Dr. James D'Orta Joins CytoVeris as Chief Medical Officer
Accomplished physician, executive, and entrepreneur with over 25 years of clinical and entrepreneurial experience to join biotechnology company in mission to enhance the surgical outcomes of breast cancer patients
FARMINGTON, Conn., Jan. 27, 2021 /PRNewswire-PRWeb/ -- CytoVeris Inc., an emerging company formed with the vision to change the paradigm in cancer surgery through the introduction of optical-based "guided surgical tools", today announced that James A. D'Orta, MD, will join the company as Chief Medical Officer. Dr. D'Orta contributes extensive clinical, business, and medical device leadership experience and brings to CytoVeris a successful history providing strategic medical oversight while positioning companies for long-term success.
"We are thrilled to have Dr. D'Orta join us as our Chief Medical Officer and are excited to leverage his expertise and extensive medical and business leadership experience to advance our mission of improving the surgical outcomes of breast cancer patients and enhancing the standards of surgical oncology," said Dr. Alan Kersey, President and CEO of CytoVeris.
Dr. D'Orta is known for his strategic insights and contributions on numerous advisory boards and organizations spanning the business, government, and non-profit sectors. He brings to CytoVeris years of medical oversight experience, having served previously as the Director of Cogentix Medical, as the Acting CEO of ACell, and was the founder and CEO of LifeLink MD.
Dr. D'Orta currently serves on numerous boards of directors including as the Director for Accuity Delivery Systems, MedStar Health, and Community Connections. He is also a faculty member at Georgetown University, George Washington University, and The University of Maryland School of Medicine.
"I'm excited to join the CytoVeris team and to help bring these innovative technologies to patients," said Dr. D'Orta. "We envision that surgeons treating patients with many types of cancer will be significantly aided by CytoVeris' technologies, the first of which being breast cancer, where there is a clear need and opportunity for us to improve surgical outcomes."
About CytoVeris:
Through the introduction of optical "guided surgical tools" that allow for the real-time detection of cancer in an intraoperative setting, CytoVeris is on a mission to change the current paradigm in cancer surgery – ensuring surgeons can remove all the cancer in a single surgical procedure. CytoVeris is leveraging the convergence of powerful optical technologies, knowledge of biochemical alteration during carcinogenesis, and explainable artificial intelligence to bring new capabilities into the hands of surgeons, and drive improvements in patient outcomes. We are also driven by a convergence – that of a passion for science and compassion for cancer patients.
For more information, please visit: https://www.cytoveris.com
Media Contact
Aliya Vandal, CytoVeris, 860-690-3887, [email protected]
SOURCE CytoVeris
Share this article